Literature DB >> 12519881

Modulation of 11 beta-hydroxysteroid dehydrogenase type 1 in mature human subcutaneous adipocytes by hypothalamic messengers.

Mark Friedberg1, Emmanouil Zoumakis, Naoki Hiroi, Tarif Bader, George P Chrousos, Ze'ev Hochberg.   

Abstract

Glucocorticoids are regulated at the prereceptor level by 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD), which interconverts inactive cortisone and active cortisol. In a previous study, we noted that patients with hypothalamic obesity had an increased ratio of cortisol/cortisone metabolites, suggesting enhanced 11 beta-HSD-1 activity. In this in vitro study, we tested the hypothesis that adipose 11 beta-HSD-1 is regulated by the hypothalamus via circulating hormones, sympathetic nervous system innervation, and/or cytokines. Preadipocytes were retrieved from sc fat from healthy nonobese individuals and differentiated in vitro to mature adipocytes. Cells were incubated with several potential effectors, and the activity of 11 beta-HSD-1 was assayed by measuring conversion of added 500 nM cortisone to cortisol. Expression of 11 beta-HSD-1 mRNA was determined by real-time PCR, whereas lipolytic effects were determined by measuring glycerol concentration in the culture medium. CRH down-regulated 11 beta-HSD-1 activity with maximal effect at 10(-9)M (65 +/- 10% of control; P < 0.001) and caused a reduction in lipolysis. Likewise, ACTH down-regulated 11 beta-HSD-1 activity with maximal effect at 10(-9) M (65 +/- 20%; P < 0.05) and reduced medium glycerol. Neither CRH nor ACTH affected 11 beta-HSD-1 mRNA expression. TNF alpha up-regulated 11 beta-HSD-1 activity maximally at 0.6 x 10(-9) M (140 +/- 20%; P < 0.001); the same cytokine increased 11 beta-HSD-1 mRNA levels to 3-fold of control (P < 0.05) and increased medium glycerol levels to 165 +/- 14% of control (P < 0.01). IL-1 beta also up-regulated 11 beta-HSD-1 activity maximally at 0.6 x 10(-9) M (160 +/- 33%; P < 0.001) and caused an increase in glycerol levels (159 +/- 11% of control; P < 0.001). Of the adrenergic agonists, salbutamol up-regulated 11 beta-HSD-1 activity maximally at 10(-7) M (162 +/- 46%; P < 0.02), and clonidine down-regulated it at 10(-7) M (82 +/- 15%; P < 0.005). We conclude that possible distinct hypothalamic mediators regulating adipose tissue 11 beta-HSD-1 might include down-regulation of 11 beta-HSD-1 activity by CRH, ACTH, and alpha 2 sympathetic stimulation, and up-regulation of the enzyme by beta 2 sympathetic stimulation and by the cytokines TNFalpha and IL-1 beta.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12519881     DOI: 10.1210/jc.2002-020510

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

1.  The corticotrophin-releasing factor/urocortin system regulates white fat browning in mice through paracrine mechanisms.

Authors:  B Lu; Y Diz-Chaves; D Markovic; A Contarino; L Penicaud; F Fanelli; S Clark; H Lehnert; D Cota; D K Grammatopoulos; A Tabarin
Journal:  Int J Obes (Lond)       Date:  2014-09-05       Impact factor: 5.095

Review 2.  Stress and obesity: the role of the hypothalamic-pituitary-adrenal axis in metabolic disease.

Authors:  Mousumi Bose; Blanca Oliván; Blandine Laferrère
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2009-10       Impact factor: 3.243

Review 3.  Review of physiology, clinical manifestations, and management of hypothalamic obesity in humans.

Authors:  Michelle Lee; Judith Korner
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

4.  Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis.

Authors:  Jeremy W Tomlinson; Mark Sherlock; Beverley Hughes; Susan V Hughes; Fiona Kilvington; William Bartlett; Rachel Courtney; Paul Rejto; William Carley; Paul M Stewart
Journal:  J Clin Endocrinol Metab       Date:  2007-01-02       Impact factor: 5.958

Review 5.  Interleukin-1 beta: a potential link between stress and the development of visceral obesity.

Authors:  Kristin J Speaker; Monika Fleshner
Journal:  BMC Physiol       Date:  2012-06-27

6.  Corticotropin-releasing hormone stimulates expression of leptin, 11beta-HSD2 and syncytin-1 in primary human trophoblasts.

Authors:  Fabian B Fahlbusch; Matthias Ruebner; Gudrun Volkert; Ramona Offergeld; Andrea Hartner; Carlos Menendez-Castro; Reiner Strick; Manfred Rauh; Wolfgang Rascher; Jörg Dötsch
Journal:  Reprod Biol Endocrinol       Date:  2012-09-12       Impact factor: 5.211

7.  Anti-inflammatory effects of levalbuterol-induced 11β-hydroxysteroid dehydrogenase type 1 activity in airway epithelial cells.

Authors:  Matthew J Randall; Shannon F Kostin; Edward J Burgess; Laura R Hoyt; Jennifer L Ather; Lennart K Lundblad; Matthew E Poynter
Journal:  Front Endocrinol (Lausanne)       Date:  2015-01-12       Impact factor: 5.555

8.  Dominant-negative STAT5B mutations cause growth hormone insensitivity with short stature and mild immune dysregulation.

Authors:  Jürgen Klammt; David Neumann; Evelien F Gevers; Shayne F Andrew; I David Schwartz; Denise Rockstroh; Roberto Colombo; Marco A Sanchez; Doris Vokurkova; Julia Kowalczyk; Louise A Metherell; Ron G Rosenfeld; Roland Pfäffle; Mehul T Dattani; Andrew Dauber; Vivian Hwa
Journal:  Nat Commun       Date:  2018-05-29       Impact factor: 14.919

9.  Regulation of 11β-hydroxysteroid dehydrogenase type 1 and 7α-hydroxylase CYP7B1 during social stress.

Authors:  Martin Vodička; Peter Ergang; Anna Mikulecká; Lenka Řeháková; Petra Klusoňová; Jakub Makal; Matúš Soták; Jana Musílková; Petr Zach; Jiří Pácha
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

10.  Corticotrophin-Releasing Factor (CRF) and the urocortins are potent regulators of the inflammatory phenotype of human and mouse white adipocytes and the differentiation of mouse 3T3L1 pre-adipocytes.

Authors:  Eirini Dermitzaki; George Liapakis; Ariadne Androulidaki; Maria Venihaki; John Melissas; Christos Tsatsanis; Andrew N Margioris
Journal:  PLoS One       Date:  2014-05-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.